Application of melanocortin-4 receptor agonist

The present invention relates to the use of a compound of Formula 1 or a pharmaceutically acceptable salt thereof for the prevention or treatment of rare genetic obesity, in particular rare genetic obesity associated with impairment of the melanocortin-4 receptor (MC4R) pathway. 本发明涉及化学式1的化合物或其药学上可接...

Full description

Saved in:
Bibliographic Details
Main Authors YU XIUZHEN, AHN HYEWON, PARK HEE-DONG
Format Patent
LanguageChinese
English
Published 15.09.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to the use of a compound of Formula 1 or a pharmaceutically acceptable salt thereof for the prevention or treatment of rare genetic obesity, in particular rare genetic obesity associated with impairment of the melanocortin-4 receptor (MC4R) pathway. 本发明涉及化学式1的化合物或其药学上可接受的盐的用途，用于预防或治疗罕见遗传性肥胖症，特别是与黑皮质素-4受体(MC4R)途径受损相关的罕见遗传性肥胖症。
Bibliography:Application Number: CN202280010488